REG - AstraZeneca PLC - Chair succession

AstraZenecaAnnouncement

29/07/2022 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220729:nRSc1646Ua&default-theme=true

RNS Number : 1646U  AstraZeneca PLC  29 July 2022

29 July 2022 07:01 BST

 

 

Michel Demaré to succeed Leif Johansson as

Non-Executive Chair of the Board

 

AstraZeneca PLC today announced the appointment of Michel Demaré as the
Chair-designate of the Board.

 

His appointment followed a robust succession planning process led by Philip
Broadley in his capacity as senior independent Non-Executive Director.

 

As previously communicated, Leif Johansson, current Chair of the Board of
AstraZeneca will be retiring at the conclusion of the Company's Annual General
Meeting in April 2023.  Michel's appointment will take effect immediately on
Leif's retirement allowing for a managed handover period over the coming
months.

 

Michel was appointed to the Board of AstraZeneca in September 2019 as an
independent Non-Executive Director and is currently Chair of the Company's
Remuneration Committee and member of the Audit Committee and the Nomination
and Governance Committee.  He is a Non-Executive Director of Vodafone Group
Plc and Louis Dreyfus Int'l Holdings BV.  He is also Chairman of IMD Business
School and Chairman of Nomoko AG.

 

Leif Johansson, AstraZeneca Chair said: "I am delighted that Michel will
succeed me following the 2023 AGM.  He is an internationally respected leader
with extensive experience in strategy, planning, execution, governance and
corporate stewardship and a proven track record leading multinational
companies, as well as experience of the pharmaceutical industry gained at
Baxter and as a member of the AstraZeneca Board.  I look forward to
undertaking a comprehensive handover in the coming months and to seeing the
continued development and success of AstraZeneca."

 

Michel Demaré, AstraZeneca Chair-designate said: "I could not be prouder to
be named Chair-designate of the Board of AstraZeneca and am excited to have
the opportunity to build on Leif's success as Chair and work with Pascal and
members of the Board and Senior Executive Team when I take on my new role in
2023."

 

Notes

 

Biography and photograph:

https://www.astrazeneca.com/our-company/leadership.html#board
(https://www.astrazeneca.com/our-company/leadership.html#board)

 

Remuneration:

Effective 1 May 2023, the fee for the Chair of the Board will be £800,000 per
annum, paid wholly in cash.  The Chair's fee was last increased in January
2018.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on Twitter @AstraZeneca (http://www.twitter.com/AstraZeneca) .

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUWUBRURUBUAR